| Term 
 
        | factors that regulate sleep |  | Definition 
 
        | age sleep history
 drug ingestion
 circadian rhythms
 |  | 
        |  | 
        
        | Term 
 
        | factors that regulate sleep-neurotransmitters |  | Definition 
 
        | catecholamines serotonin
 histamine
 acetylcholine
 adenosine
 GABA
 |  | 
        |  | 
        
        | Term 
 
        | factors that regulate sleep-neuromodulators |  | Definition 
 
        | growth hormone prolactin
 melatonin
 endogenous peptides
 |  | 
        |  | 
        
        | Term 
 
        | ligands acting at the BZD binding site |  | Definition 
 
        | benzodiazepines non-benzodiazepines
 BZD antagonists
 Inverse BZD agonists
 |  | 
        |  | 
        
        | Term 
 
        | ligands acting at other sites |  | Definition 
 
        | barbiturates alcohol
 GABA blockers
 GABA agonist
 etomidate and propofol
 |  | 
        |  | 
        
        | Term 
 
        | chlordiazepoxide (Librium) |  | Definition 
 
        | benzodiazepine slow elimination rate
 1st benzodiazepine
 used as an anxiolytic and for alcohol withdrawal
 accumulation of metabolites
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepines slow elimination rate
 prototypical benzodiazepine
 used as an anxiolytic, for alcohol withdrawal, and for treatment of convulsive disorders, accumulation of metabolites
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepines slow elimination rate
 used as a hypnotic, accumulation of metabolites
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepines slow elimination rate
 used as an anxiolytic, for alcohol withdrawal, and for treatment of convulsive disorders
 accumulation of metabolites
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepines slow elimination rate
 used as a hypnotic
 accumulation of metabolites
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepines slow elimination rate
 currently unavailable in the US
 used as an anxiolytic
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepines intermediate eliminate rate
 withdrawal symptoms can present if abrupt discontinuation occurs, used as n anxiolytic and anesthetic
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepines intermediate eliminate rate
 used as an anxiolytic and as a hypnotic
 |  | 
        |  | 
        
        | Term 
 
        | clonazepam (Klonopin) C-IV
 |  | Definition 
 
        | benzodiazepines intermediate eliminate rate
 tolerance may develop with prolonged use, used as an anticonvulsant
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepines intermediate eliminate rate
 used as an anxiolytic and for alcohol withdrawal
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepines intermediate eliminate rate
 used as a short-term hypnotic
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepines intermediate eliminate rate
 discontinued
 used as a short-term hypnotic
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepines rapid elimination rate
 rapid anesthesia
 |  | 
        |  | 
        
        | Term 
 
        | triazolam (Halcion, discontinued) |  | Definition 
 
        | used as a short-term hypnotic |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepine antagonist therapeutic use --> BZD overdose
 initial dose- 0.2 mg IV over 30 sec, if desired consciousness not obtained increase to 0.3mg IV over 30 sec
 max total cumulative dose- 3 mg (usual range 1-3mg)
 side effects: induced convulsions, panic attacks, agitation, confusion, nausea and vomiting, headache
 |  | 
        |  | 
        
        | Term 
 
        | zolpidem (Ambien, Ambien CR) C-IV
 |  | Definition 
 
        | non-benzodiazepine short-term treatment of insomnia
 with difficulty of sleep-onset
 ambien CR for sleep maintenance
 "A-minus" and "Zombie pills"
 dangerous aid for sexual assault
 teen party drug
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | non-benzodiazepine short-term treatment of insomnia
 MOA: facilitate GABA-mediated inhibition, act on GABAa receptor-BZ1
 rapid acting
 rapidly eliminated
 little tolerance or dependence
 short-term treatment- 7 to 10 days
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | non-benzodiazepine MOA: facilitate GABA
 active enantiomer of zopiclone- 50x greater affinity
 treatment of insomnia- able to sleep all through the night with fewer interruptions, approved for long-term use (low tolerance over time, based on 6 mo study)
 temporary side effect: unpleasant metallic taste
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | benzodiazepine not available in the US
 "roofies"
 DEA recommends changing to C-I
 anterograde amnesia- dangerous aid for sexual assault
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | anticonvulsants phenobarbital (Luminal)
 mephobarbital (Mebaral)
 |  | 
        |  | 
        
        | Term 
 
        | short to intermediate acting barbiturates |  | Definition 
 
        | sedative-hypnotics amobarbital (Amytal)
 butabarbital (Butisol Sodium)
 pentobarbital (Nembutal)
 secobarbital (Seconal)
 aprobarbital (Alurate)
 |  | 
        |  | 
        
        | Term 
 
        | ultra-short acting barbiturates |  | Definition 
 
        | IV anesthetics thiopental (Pentothal)
 methohexital (Brevital Sodium)
 thiamylal (Surital)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | GABAb receptor agonist skeletal muscle relaxant (treatment of alcoholism)
 |  | 
        |  | 
        
        | Term 
 
        | Gamma-Hydroxybutyric Acid (GHB) |  | Definition 
 
        | GABAb receptor agonist central nervous system depressant
 |  | 
        |  | 
        
        | Term 
 
        | Phaclofen, Saclofen, and 2-Hydroxysaclofen |  | Definition 
 
        | GABAb receptor antagonist |  | 
        |  | 
        
        | Term 
 
        | Xyrem (Sodium Oxybate, GHB) |  | Definition 
 
        | CI-->illicit use CII-->medical use
 available only to prescribers enrolled in the Xyrem Patient Success Program
 -dispensed to the patient through a designated centralized pharmacy
 -patients  must be seen every 3 months
 -rx can be written for a maximum of 3 mo supply
 -1st Rx can only be written for a 1 mo supply
 actions
 -with concomitant stimulant use: decrease excessive daytime sleepiness, increase daytime wakefulness
 -decrease cataplexy
 pharmacology:
 -GABAb, GABAa, and GHB(?) receptors
 dosing: oral solution (500mg/mL), initial dose- 4.5g/night in 2 divided doses-1st dose given at bedtime, 2nd dose given 2.5 to 4 hours later, doses may be increased or adjusted in 2 week intervals, average dose: 6 to 9 g/night.
 concerns: mechanism (?), other agents, red tape, abuse and misuse
 |  | 
        |  | 
        
        | Term 
 
        | Gamma-Hydroxybutyric Acid (GHB) |  | Definition 
 
        | street names: "liquid ecstasy", "Liquid X", "Juice", "Grievous Bodily Harm", "Scoops", "Georgia Home Boy" Background: 1960's to today: anesthetic, fat burner, GH promoter, "Raves", Date Rape, and body building
 Pharmacology: CNS depression-->dose dependent, dizziness, drowsiness, coma
 -patients often awaken spontaneously
 -prodrugs: Gamma-Butryolactone(GBL), 1,4-Butanediol
 |  | 
        |  | 
        
        | Term 
 
        | Ramelteon (Rozerem): Melatonin Agonist |  | Definition 
 
        | MOA: high affinity for MT1 and MT2 melatonin receptors, receptors located in the suprachiasmatic nucleus (SCN), servse as a "master clock" by regulating circadian rhythms-loss of melatonin in aging and alzheimer's metabolism: CYP1A2, avoid with other CYP1A2 inhibitors-fluvoxamine and ciprofloxacin, use with caution in patients with moderate hepatic impairment and avoid use in patients with severe hepatic impairment
 treatment of insomnia characterized by difficulty with sleep onset
 non-controlled substance sleep aid
 no abuse, withdrawal, or dependency
 negligible risk for next-day "hangover" effects
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | antidepressant unlabeled/investigational use
 |  | 
        |  | 
        
        | Term 
 
        | antihistamines (OTC drugs) |  | Definition 
 
        | diphenhydramine doxylamine
 pyrilamine
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | dietary supplement 5HT precursor
 withdrawn with market due to contamination-caused eosinophilia-myalgia syndrome
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | nutraceutical traveler's jet lag
 work shifts-insomnia
 sleep disturbances
 signs and symptoms of overdose
 ataxia-drowsiness
 |  | 
        |  | 
        
        | Term 
 
        | lemon balm (Melissa officinalis) |  | Definition 
 
        | herb use with caution in patients with thyroid problems
 |  | 
        |  | 
        
        | Term 
 
        | valerian (Valerian officinlis) |  | Definition 
 
        | herb insomnia
 hepatotoxicity has been noted
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | matricaria chamomilla matricaria recutita
 herb
 mild sedative
 avoid use in patients with a ragweed allergy
 use with caution in patients using cytochrome P450 substrates
 |  | 
        |  | 
        
        | Term 
 
        | Kava Kava (Piper methysticum) |  | Definition 
 
        | herb insomnia
 possibly hepatotoxic
 |  | 
        |  | 
        
        | Term 
 
        | structure activity relationships of benzodiazepines |  | Definition 
 
        | 1 position alkylation-->source of active metabolites 2 position NH2 or N(CH3)2 is active; oxo is active (i.e. valium)
 3 position has decreased activity; 3-OH rapid excretion
 4-Nonoxide is active
 substitution on 5-phenyl has decreased activity
 7 position with an electronegative group is good
 anealating the 1-2 bond with an "electron rich" ring (triazole or imidazole) yields high affinity and decreased half life
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | loss of consciousness and reflexes, nausea and vomiting, headache, seizures, death |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | supportive treatment-no antagonist, other sedative-hypnotics-including alcohol, amnesia, date rape-examinations and counseling |  | 
        |  |